Moss, 30 April 2024

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the first quarter 2024.

Highlights

Record sales of NOK 38.5 million in 1Q24, up 22% vs 1Q23 (19% organic growth)

EBITDA of NOK 4.8 million in 1Q24 versus NOK -0.5 million in 1Q23

Gross margin of 53% positively influenced by favourable product mix and
finalisation of integration with Getica AB, which was acquired in July 2023

Sales of fCAL® turbo increased 44% in 1Q24 compared to 1Q23 

Continued solid development for third party sales which increased 31% in 1Q24
compared to 1Q23 

New KDIGO Guidelines issued during 1Q24 recommends increased use of Cystatin C

Significant advancements achieved in the technical development and production
upscaling of the NT-proBNP assay 


Webcast

The company will present the results today at 09.00 am, followed by a Q&A
session. Join the webcast and submit questions via the following link:

https://attendee.gotowebinar.com/register/7635969055696914784

The webcast will be available on the company website after the presentation. 

IR contact:

Njaal Kind, CEO
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Ole Sørlie, Business
Controller at Gentian Diagnostics ASA, on 30 April 2024 at 08:00 CET.


About Gentian 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.